UK's Oxford Nanopore H1 revenue rises on clinical, biopharma segements growth

Oxford Nanopore Technologies

19/08/2026 07:09

Overview
UK molecular sensing tech firm's H1 revenue rose 10.5% yr/yr, led by EMEAI growth
Gross margin improved by 400bps to 62.2% on yield gains and new pricing model adoption
Adjusted EBITDA loss more than halved yr/yr, reflecting cost discipline and higher gross profit

Outlook
Company maintains FY26 revenue growth guidance of 16-20% CC, excluding $20 mln licensing revenue
Company expects FY26 gross margin of about 62%, excluding $20 mln licensing revenue
Oxford Nanopore targets adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28

Result Drivers
END-MARKET GROWTH - Revenue growth was led by Clinical and BioPharma segments, with Research remaining the largest contributor
REGIONAL PERFORMANCE - Strong growth in EMEAI and AMR offset by APAC decline, mainly due to lower China sales
MARGIN IMPROVEMENT - Gross margin rose on manufacturing yield gains, new pricing model, and absence of prior inventory charge

Company press release: ID:nRSS2917Ra

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
GBP 116.70 mln
 
H1 Net Loss
 
GBP 48 mln
 
H1 Adjusted EBITDA
 
-GBP 22.10 mln
 
H1 Gross Margin
 
62.20%
 
H1 Gross Profit
 
GBP 72.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Oxford Nanopore Technologies PLC is GBp185.00, about 51.4% above its August 18 closing price of GBp122.20

Reuters Recommended Reads
Aug 19 - Sweden's BICO Q2 revenue, profitability improve on strong demand
Aug 18 - Denmark's Coloplast Q3 revenue up on Chronic Care, Urology growth
Aug 19 - Sensirion H1 profit jumps on medical demand; lifts outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)